Summary
24.46 0.32(1.30%)05/16/2024
Alkermes plc (ALKS)
Alkermes plc (ALKS)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 2.03 | 0.20 | -5.17 | -7.90 | -2.61 | -20.45 | -10.91 | 347.09 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 24.59 | |
| Open | 24.22 | |
| High | 24.79 | |
| Low | 24.07 | |
| Volume | 1,718,978 | |
| Change | 0.49 | |
| Change % | 2.03 | |
| Avg Volume (20 Days) | 1,790,678 | |
| Volume/Avg Volume (20 Days) Ratio | 0.96 | |
| 52 Week Range | 22.01 - 33.71 | |
| Price vs 52 Week High | -27.05% | |
| Price vs 52 Week Low | 11.72% | |
| Range | 1.53 | |
| Gap Up/Down | -0.21 | |
Fundamentals | ||
| Market Capitalization (Mln) | 4,085 | |
| EBIDTA | 538,672,000 | |
| PE Ratio | 7.1577 | |
| PEG Ratio | -1,057.2900 | |
| WallStreet Target Price | 34.45 | |
| Book Value | 7.4170 | |
| Earnings Per Share | 3.3600 | |
| EPS Estimate Current Quarter | 0.5800 | |
| EPS Estimate Next Quarter | 0.7400 | |
| EPS Estimate Current Year | 2.6900 | |
| EPS Estimate Next Year | 2.5900 | |
| Diluted EPS (TTM) | 3.3600 | |
| Revenues | ||
| Profit Marging | 0.2517 | |
| Operating Marging (TTM) | 0.1236 | |
| Return on asset (TTM) | 0.1465 | |
| Return on equity (TTM) | 0.5045 | |
| Revenue TTM | 1,726,182,016 | |
| Revenue per share TTM | 10.3400 | |
| Quarterly Revenue Growth (YOY) | 0.2180 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 893,687,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 7.1577 | |
| Forward PE | 9.5511 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.3924 | |
| Revenue Enterprise Value | 2.2115 | |
| EBITDA Enterprise Value | 7.0815 | |
| Shares | ||
| Shares Outstanding | 169,220,992 | |
| Shares Float | 160,829,626 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.11 | |
| Insider (%) | 1.25 | |
| Institutions (%) | 104.63 | |
05/14 07:00 EST - prnewswire.com
Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
̶ Results from Long-Term Safety Study and Data from Healthcare Resource Utilization Research Offer Insights into Treatment Experiences for People Living with Schizophrenia or Bipolar I Disorder ̶ DUBLIN , May 14, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry franchise products—LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil)—at four scientific conferences this spring. These meetings take place during Mental Health Awareness Month in May, an important moment in the year to raise awareness about mental health conditions, support people living with these complex diseases, and honor the work of healthcare providers.
Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
̶ Results from Long-Term Safety Study and Data from Healthcare Resource Utilization Research Offer Insights into Treatment Experiences for People Living with Schizophrenia or Bipolar I Disorder ̶ DUBLIN , May 14, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry franchise products—LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil)—at four scientific conferences this spring. These meetings take place during Mental Health Awareness Month in May, an important moment in the year to raise awareness about mental health conditions, support people living with these complex diseases, and honor the work of healthcare providers.
05/02 12:41 EST - zacks.com
Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates
Alkermes' (ALKS) earnings and revenues miss first-quarter 2024 estimates. However, revenues rise year over year on strong proprietary product sales.
Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates
Alkermes' (ALKS) earnings and revenues miss first-quarter 2024 estimates. However, revenues rise year over year on strong proprietary product sales.
05/02 07:00 EST - prnewswire.com
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
DUBLIN , May 2, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk. In connection with the closing of the transaction, Alkermes will receive a one-time cash payment for the facility and certain related assets of approximately $91 million.
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
DUBLIN , May 2, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk. In connection with the closing of the transaction, Alkermes will receive a one-time cash payment for the facility and certain related assets of approximately $91 million.
05/01 10:35 EST - zacks.com
Alkermes (ALKS) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Alkermes (ALKS) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Alkermes (ALKS) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Alkermes (ALKS) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
05/01 09:31 EST - zacks.com
Alkermes (ALKS) Q1 Earnings and Revenues Miss Estimates
Alkermes (ALKS) came out with quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.59 per share. This compares to earnings of $0.01 per share a year ago.
Alkermes (ALKS) Q1 Earnings and Revenues Miss Estimates
Alkermes (ALKS) came out with quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.59 per share. This compares to earnings of $0.01 per share a year ago.
05/01 07:00 EST - prnewswire.com
Alkermes plc Reports First Quarter 2024 Financial Results
— First Quarter Revenues of $350.4 Million — — GAAP Net Income from Continuing Operations of $38.9 Million and Diluted GAAP Earnings per Share from Continuing Operations of $0.23 — — Company Reiterates 2024 Financial Expectations — DUBLIN , May 1, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2024. "The first quarter of 2024 marks our first full quarter as a profitable, pure-play neuroscience company.
Alkermes plc Reports First Quarter 2024 Financial Results
— First Quarter Revenues of $350.4 Million — — GAAP Net Income from Continuing Operations of $38.9 Million and Diluted GAAP Earnings per Share from Continuing Operations of $0.23 — — Company Reiterates 2024 Financial Expectations — DUBLIN , May 1, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2024. "The first quarter of 2024 marks our first full quarter as a profitable, pure-play neuroscience company.
04/24 07:00 EST - prnewswire.com
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
DUBLIN , April 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared to placebo in patients with narcolepsy type 1 (NT1). ALKS 2680 is the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy, a chronic, neurological disorder characterized by excessive daytime sleepiness.
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
DUBLIN , April 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared to placebo in patients with narcolepsy type 1 (NT1). ALKS 2680 is the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy, a chronic, neurological disorder characterized by excessive daytime sleepiness.
04/22 15:16 EST - zacks.com
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?
Alkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate incremental sales and combat stiff competition in 2024.
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?
Alkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate incremental sales and combat stiff competition in 2024.
04/17 16:00 EST - prnewswire.com
Alkermes to Report First Quarter Financial Results on May 1, 2024
DUBLIN , April 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.
Alkermes to Report First Quarter Financial Results on May 1, 2024
DUBLIN , April 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.
04/17 11:06 EST - zacks.com
Alkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
04/11 11:16 EST - zacks.com
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study
Alkermes (ALKS) reports positive top-line data from a phase Ib, proof-of-concept study investigating ALKS 2680 for the treatment of narcolepsy.
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study
Alkermes (ALKS) reports positive top-line data from a phase Ib, proof-of-concept study investigating ALKS 2680 for the treatment of narcolepsy.
04/10 10:46 EST - zacks.com
Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
04/09 16:29 EST - seekingalpha.com
Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data
Alkermes reports positive Phase 1 results for ALKS-2680 in narcolepsy and idiopathic hypersomnia, with significant efficacy and manageable side effects. The company plans to proceed with a Phase 2 study for ALKS-2680 in Narcolepsy Type 2 later this year. Q4 earnings show robust revenue growth, led by Lybalvi, which significantly outpaced other products with 61% year-over-year growth.
Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data
Alkermes reports positive Phase 1 results for ALKS-2680 in narcolepsy and idiopathic hypersomnia, with significant efficacy and manageable side effects. The company plans to proceed with a Phase 2 study for ALKS-2680 in Narcolepsy Type 2 later this year. Q4 earnings show robust revenue growth, led by Lybalvi, which significantly outpaced other products with 61% year-over-year growth.
04/09 09:49 EST - seekingalpha.com
Alkermes plc: Collecting The Fruits Of The 2023 Spinoff
Alkermes' spinoff transaction with Mural Oncology resulted in cost cutting and higher EBITDA margins, with strong 2023 profitability gains expected to continue into 2024. ALKS stock is currently undervalued compared to peers, but capital allocation initiatives such as dividends and buybacks could help close the valuation gap. Risks include potential delays or lower-than-expected shareholder remuneration and competition from generics, but overall, the target price for Alkermes is $34 with a 30% upside potential.
Alkermes plc: Collecting The Fruits Of The 2023 Spinoff
Alkermes' spinoff transaction with Mural Oncology resulted in cost cutting and higher EBITDA margins, with strong 2023 profitability gains expected to continue into 2024. ALKS stock is currently undervalued compared to peers, but capital allocation initiatives such as dividends and buybacks could help close the valuation gap. Risks include potential delays or lower-than-expected shareholder remuneration and competition from generics, but overall, the target price for Alkermes is $34 with a 30% upside potential.
04/09 07:00 EST - prnewswire.com
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
— Orexin 2 Receptor Agonist ALKS 2680 Demonstrated Clinically Meaningful and Statistically Significant Improvements from Baseline in Mean Sleep Latency Compared to Placebo at All Doses Tested in Both Narcolepsy Type 2 and Idiopathic Hypersomnia — — ALKS 2680 Was Generally Well Tolerated at All Doses Tested — — Dose-Dependent Effects and Pharmacodynamic Profile Support Advancement Into Planned Phase 2 Study — DUBLIN , April 9, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts of a phase 1b, proof-of-concept study evaluating ALKS 2680, the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy. ALKS 2680 data demonstrated clinically meaningful and statistically significant improvements from baseline in mean sleep latency on the Maintenance of Wakefulness Test (MWT) compared to placebo at all doses tested.
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
— Orexin 2 Receptor Agonist ALKS 2680 Demonstrated Clinically Meaningful and Statistically Significant Improvements from Baseline in Mean Sleep Latency Compared to Placebo at All Doses Tested in Both Narcolepsy Type 2 and Idiopathic Hypersomnia — — ALKS 2680 Was Generally Well Tolerated at All Doses Tested — — Dose-Dependent Effects and Pharmacodynamic Profile Support Advancement Into Planned Phase 2 Study — DUBLIN , April 9, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts of a phase 1b, proof-of-concept study evaluating ALKS 2680, the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy. ALKS 2680 data demonstrated clinically meaningful and statistically significant improvements from baseline in mean sleep latency on the Maintenance of Wakefulness Test (MWT) compared to placebo at all doses tested.
04/08 07:00 EST - prnewswire.com
Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
DUBLIN , April 8, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the oral presentation of clinical data at the 2024 Congress of the Schizophrenia International Research Society (SIRS), which took place April 3-7, 2024 in Florence, Italy. Analyses were presented from a phase 3, open-label extension study assessing the long-term safety, tolerability and durability of treatment effect of LYBALVI® (olanzapine and samidorphan) in patients who received up to four years of treatment.
Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
DUBLIN , April 8, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the oral presentation of clinical data at the 2024 Congress of the Schizophrenia International Research Society (SIRS), which took place April 3-7, 2024 in Florence, Italy. Analyses were presented from a phase 3, open-label extension study assessing the long-term safety, tolerability and durability of treatment effect of LYBALVI® (olanzapine and samidorphan) in patients who received up to four years of treatment.
04/02 13:16 EST - zacks.com
Why Alkermes (ALKS) is Poised to Beat Earnings Estimates Again
Alkermes (ALKS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Alkermes (ALKS) is Poised to Beat Earnings Estimates Again
Alkermes (ALKS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
03/20 09:50 EST - zacks.com
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
03/13 13:46 EST - zacks.com
3 Reasons Why Alkermes (ALKS) Is a Great Growth Stock
Alkermes (ALKS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
3 Reasons Why Alkermes (ALKS) Is a Great Growth Stock
Alkermes (ALKS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
03/12 10:50 EST - zacks.com
Here's Why Alkermes (ALKS) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Alkermes (ALKS) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.